You are here

Article info

Article menu

Download PDFPDF

Case Report
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

Authors

  1. ↵a (617)935-1649 victoria.wang{at}ucsf.edu
  2. ↵b Anatoly.urisman{at}ucsf.edu
  3. ↵c lalbacker{at}foundationmedicine.com
  4. ↵d sali{at}foundationmedicine.com
  5. ↵e vmiller{at}foundationmedicine.com
  6. ↵f Rahul.aggarwal{at}ucsf.edu
  7. ↵g David.jablons{at}ucsf.edu
View Full Text

Citation

Wang VE, Urisman A, Albacker L, et al
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
Journal for ImmunoTherapy of Cancer 2017;5:75. doi: 10.1186/s40425-017-0281-y

Publication history

  • Received June 14, 2017
  • Accepted September 1, 2017
  • First published September 19, 2017.
Online issue publication 
February 09, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.